Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose vs low-dose empagliflozin on fatty liver indices in type 2 diabetes
IRCT20250524065869N1Phase 3Completed
- Sponsor
- Aja University of Medical Sciences
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of empagliflozin in type 2 diabetes mellitus (T2DM) and steatosis (2 arms), sponsored by Aja University of Medical Sciences. Started Jun 2025; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)steatosis
Beyond the preview
Go deeper on IRCT20250524065869N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250524065869N1.